Long-term Effect of Lanthanum Carbonate on Bone

Shire

Status: Completed

Conditions: Hyperphosphatemia

Treatments: Drug: Lanthanum carbonate

Study type: Observational

Funder types: Industry

Identifiers

NCT00557323

SPD405-402

Details and patient eligibility

About

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.

Enrollment: 34 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Any patient who had exposure to lanthanum carbonate in SPD405-309

Trial design

34 participants in 1 patient group

1

Description:

Patients being treated for hyperphosphatemia with any marketed product

Treatment:

Drug: Lanthanum carbonate